Skye Bioscience, Inc.
SKYE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $6 | $6 | $3 |
| G&A Expenses | $18 | $8 | $6 | $5 |
| SG&A Expenses | $18 | $8 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$6 | $21 | $6 | $0 |
| Operating Expenses | $30 | $35 | $18 | $8 |
| Operating Income | -$30 | -$35 | -$18 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | -$3 | -$1 | -$1 |
| Pre-Tax Income | -$27 | -$38 | -$19 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$38 | -$19 | -$9 |
| % Margin | – | – | – | – |
| EPS | -0.73 | -5.37 | -8.77 | -5 |
| % Growth | 86.4% | 38.8% | -75.4% | – |
| EPS Diluted | -0.73 | -5.37 | -8.77 | -5 |
| Weighted Avg Shares Out | 36 | 7 | 2 | 2 |
| Weighted Avg Shares Out Dil | 36 | 7 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$37 | -$19 | -$8 |
| % Margin | – | – | – | – |